Stryker continues to outpace medtech peers with organic growth above 8% driven by Mako robotic surgery platform installed base expansion and procedure recovery from COVID backlog. Orthopaedic procedure volume durable as aging demographics offset GLP-1 surgical deferral concerns. Acquisition-led growth strategy proven. Neurovascular and endoscopy diversification adds resilience. Operating margin expansion path supports earnings growth above revenue growth.
Signals scoped to US · Company-specific tagging coming soon.